- Home
- MYGN vs BHE Comparison
MYGN vs BHE Comparison
Compare MYGN & BHE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- BHE
- Stock Information
- Founded
- MYGN 1991
- BHE 1979
- Country
- MYGN United States
- BHE United States
- Employees
- MYGN N/A
- BHE N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- BHE Electrical Products
- Sector
- MYGN Health Care
- BHE Technology
- Exchange
- MYGN Nasdaq
- BHE Nasdaq
- Market Cap
- MYGN 1.3B
- BHE 1.4B
- IPO Year
- MYGN 1995
- BHE 1990
- Fundamental
- Price
- MYGN $8.80
- BHE $38.38
- Analyst Decision
- MYGN Hold
- BHE Strong Buy
- Analyst Count
- MYGN 15
- BHE 3
- Target Price
- MYGN $20.43
- BHE $43.00
- AVG Volume (30 Days)
- MYGN 875.3K
- BHE 579.0K
- Earning Date
- MYGN 05-06-2025
- BHE 04-30-2025
- Dividend Yield
- MYGN N/A
- BHE 1.77%
- EPS Growth
- MYGN N/A
- BHE N/A
- EPS
- MYGN N/A
- BHE 1.72
- Revenue
- MYGN $837,600,000.00
- BHE $2,656,105,000.00
- Revenue This Year
- MYGN $3.03
- BHE $4.55
- Revenue Next Year
- MYGN $8.31
- BHE $7.17
- P/E Ratio
- MYGN N/A
- BHE $22.31
- Revenue Growth
- MYGN 11.21
- BHE N/A
- 52 Week Low
- MYGN $8.53
- BHE $28.64
- 52 Week High
- MYGN $29.30
- BHE $52.57
- Technical
- Relative Strength Index (RSI)
- MYGN 27.06
- BHE 41.45
- Support Level
- MYGN $8.53
- BHE $39.74
- Resistance Level
- MYGN $10.30
- BHE $41.55
- Average True Range (ATR)
- MYGN 0.44
- BHE 1.11
- MACD
- MYGN -0.01
- BHE -0.09
- Stochastic Oscillator
- MYGN 15.08
- BHE 23.74
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About BHE Benchmark Electronics Inc.
Benchmark Electronics Inc is engaged in product designing, engineering services, technology solutions, and advanced manufacturing services (electronic manufacturing services (EMS) and precision technology services). It serves various industries, including aerospace & defense (A&D), medical technologies, complex industrials, semiconductor capital equipment, next-generation telecommunications, and high-end computing. Its geographical segments are the Americas, Asia and Europe of which key revenue is derived from the Americas.